公开(公告)号：US20190055506A1

公开(公告)日：2019-02-21

申请号：US15573381

申请日：2016-05-11

Applicant: XIAMEN UNIVERSITY ,  XIAMEN INNODX BIOTECH CO., LTD

Inventor： Shengxiang GE ,  Shiyin ZHANG ,  Feihai XU ,  Jin WANG ,  Jinjie LI ,  Jun ZHANG ,  Ningshao XIA

IPC: C12M1/38 ,  C12M1/24 ,  C12Q1/6844 ,  B01L3/00

Abstract: Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.

公开(公告)号：US20180031556A1

公开(公告)日：2018-02-01

申请号：US15549443

申请日：2016-01-26

Applicant: XIAMEN UNIVERSITY

Inventor： Shengxiang GE ,  Jinjie LI ,  Xi HUANG ,  Tingdong LI ,  Jun ZHANG ,  Ningshao XIA

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  G01N33/53 ,  G01N33/543 ,  G01N33/569 ,  G01N33/56994 ,  G01N2333/045 ,  G01N2469/20 ,  G01N2800/50 ,  G01N2800/52

Abstract: The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore.

公开(公告)号：US20160145320A1

公开(公告)日：2016-05-26

申请号：US14781391

申请日：2014-04-02

Applicant: XIAMEN UNIVERSITY

Inventor： Yixin CHEN ,  Qingbing ZHENG ,  Rui LI ,  Chenguang SHEN ,  Shaojun KE ,  Wenxin LUO ,  Honglin CHEN ,  Ningshao XIA

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10

Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.

Abstract translation: 本发明涉及识别流感病毒血凝素（HA）蛋白HA1结构域上的抗原表位的抗体，用于产生抗体的细胞系及其用途。 根据本发明的抗体可以特异性结合不同HA亚型的HA1结构域，并特异性结合H1亚型（包括季节性H1N1和2009大流行H1N1）和流感病毒H5亚型的血凝素（HA）蛋白的HA1结构域。 因此，本发明还涉及用于预防和/或治疗H1亚型和H5亚型流感病毒感染的疫苗或药物组合物和/或由包含本发明的抗体的感染（例如流感）引起的疾病。

公开(公告)号：US20240408594A1

公开(公告)日：2024-12-12

申请号：US18697740

申请日：2022-11-11

Applicant: XIAMEN UNIVERSITY ,  XIAMEN INNODX BIOTECH CO., LTD

Inventor： Dongxu ZHANG ,  Runxin GAO ,  Shaolei HUANG ,  Yulin HUANG ,  Guoqiang LIU ,  Jiayu YANG ,  Juntian ZENG ,  Liuwei SONG ,  Shengxiang GE ,  Jun ZHANG ,  Ningshao XIA

IPC: B01L3/00 ,  B01L7/00

Abstract: The present disclosure relates to a microfluidic chip and a microfluidic chip detection system. The microfluidic chip including: a storage member provided with a groove therein, at least two storage chambers being disposed around the groove; a base disposed at one end of the storage member away from the groove, a reaction chamber being disposed on the base; and a valve disposed in the groove, the valve being configured to operatively communicate any one of the at least two storage chambers with the reaction chamber. The present disclosure can lead the solution in any storage chamber to the reaction chamber or lead the solution in the reaction chamber to any storage chamber by operating the valve, so that the solution transfer is realized, the structure is simple and compact, the length of the flow channels can be greatly shortened, and the detection efficiency is improved.

公开(公告)号：US20240000919A1

公开(公告)日：2024-01-04

申请号：US18252836

申请日：2021-11-12

Applicant: XIAMEN UNIVERSITY ,  XIAMEN INNOVAX BIOTECH CO., LTD.

Inventor： Ying GU ,  Tingting DENG ,  Hui ZHANG ,  Fang HUANG ,  Gege CHEN ,  Yanling LIN ,  Shaowei LI ,  Ningshao XIA

IPC: A61K39/21 ,  C12N7/00 ,  C07K14/005 ,  A61P31/18

CPC classification number: A61K39/21 ,  C12N7/00 ,  C07K14/005 ,  A61P31/18 ,  C12N2740/16122 ,  C12N2740/16134 ,  C07K2319/40 ,  C12N2740/16171 ,  A61K2039/645

Abstract: Provided are a newly designed HIV-1 Env trimer protein, and an HIV-1 pseudovirus and virus expressing the Env trimer protein, and the use thereof for the prevention and/or treatment of HIV infection.

公开(公告)号：US20230324396A1

公开(公告)日：2023-10-12

申请号：US17790438

申请日：2020-12-25

Applicant: XIAMEN UNIVERSITY ,  XIAMEN INNODX BIOTECH CO., LTD ,  BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.

Inventor： Tingdong LI ,  Shengxiang GE ,  Xiaoyi GUO ,  Congming HONG ,  Liuwei SONG ,  Shunhua WEN ,  Jiabao TANG ,  Jun ZHANG ,  Ningshao XIA

IPC: G01N33/574 ,  C07K14/05

CPC classification number: G01N33/57488 ,  C07K14/05 ,  G01N2333/05 ,  G01N2469/20

Abstract: Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.

公开(公告)号：US20230323369A1

公开(公告)日：2023-10-12

申请号：US18002988

申请日：2021-06-24

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Quan YUAN ,  Jiali CAO ,  Yali ZHANG ,  Mingfeng WANG ,  Jian MA ,  Tianying ZHANG ,  Jun ZHANG ,  Ningshao XIA

IPC: C12N15/85 ,  C12N15/52 ,  G01N33/50 ,  C12N9/02

CPC classification number: C12N15/52 ,  C12N9/0069 ,  C12N15/85 ,  G01N33/5023 ,  C12N2510/00 ,  C12N2730/10122 ,  G01N2333/02

Abstract: The present invention belongs to the field of virology, in particular to the field of hepatitis B virus treatment. Provided are a model and a method for screening HBV cccDNA inhibitors. According to the screening model and the method, the detection of a split luciferase is used as an alternative index ofHBV cccDNA detection, and a cccDNA-targeted drug can be screened in high throughput.

公开(公告)号：US20230174592A1

公开(公告)日：2023-06-08

申请号：US17997465

申请日：2021-04-30

Applicant: YANG SHENG TANG COMPANY, LTD. ,  XIAMEN UNIVERSITY

Inventor： Yali ZHANG ,  Shaojuan WANG ,  Yangtao WU ,  Wangheng HOU ,  Jianghui YE ,  Juan WANG ,  Tianying ZHANG ,  Tong CHENG ,  Quan YUAN ,  Ningshao XIA

IPC: C07K14/165 ,  C12N15/63 ,  G01N33/58 ,  C12N5/071 ,  C07K14/705

CPC classification number: C07K14/165 ,  C12N15/63 ,  G01N33/582 ,  C12N5/0602 ,  C07K14/705 ,  C07K2319/60 ,  C07K2319/02

Abstract: Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.

公开(公告)号：US20220235117A1

公开(公告)日：2022-07-28

申请号：US17613322

申请日：2020-05-22

Applicant: XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

Inventor： Wenxin LUO ,  Can WEN ,  Xinchu XIANG ,  Jixian TANG ,  Yangtao WU ,  Tianying ZHANG ,  Quan YUAN ,  Ningshao XIA

IPC: C07K16/08 ,  A61P31/20

Abstract: Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

公开(公告)号：US20210236618A1

公开(公告)日：2021-08-05

申请号：US15734750

申请日：2019-06-04

Applicant: Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

Inventor： Shaowei LI ,  Xinlin LIU ,  Yurou YANG ,  Jie CHEN ,  Daning WANG ,  Ningshao XIA

IPC: A61K39/12 ,  C07K14/025 ,  C12N7/00

Abstract: The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.